跳至主要内容
临床试验/CTRI/2020/07/026694
CTRI/2020/07/026694已完成2 期

A Open labelled double arm non randomized phase II clinical trial, to evaluate the therapeutic efficacy of siddhar yogam therapy and siddha kalpa medicine Chukku Karpam (Internal) in the management of cegana vatham (Cervical spondylosis)

Government siddha medical college and hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年7月23日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Comparison of change from baseline in Universal Pain Assessment scale at day 30 between GROUP I and GROUP II

研究概览

简要总结

cervical spondylosis is a common degenerative condition of the cervical spine. it is most likely caused by age related changes in the intervertebral discs. in cervical spine, some degree of degenerative change is a normal radiological findings in the middle aged and elderly. Degenaration of the intervertebral discs and secondary osteoarthrosis (cervical spondylosis) is often asymptomatic but may be associated with neurological dysfunction. The C4/5, C5/6, C6/7 vertberae are most commonly affected

Siddhar Yogam therapy is a therapy for the combination of physical and mental excercises

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
25.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Neck pain Radiating pain towards upper limbs with or without numbness in the upper limbs giddiness and neck stiffness Patients who are willing to give blood samples for laboratory investigation Patients who are willling to take x ray before and after treatment willing for admission in IPD for 30 days or willing to OPD regularly Patients who are willing to participate in this study with knowledge of potential risks and who are willing to sign the informed consent.

排除标准

  • Cardiac Disease Benign and malignant Neoplasm spina bifida ankylosing spondylosis Congenital anomalies of spine Severe Osteoporosis of cervical spine Cervical rib pregnant women and lactating mother Trauma Syringomyelia Tuberculosis in spine Diabetes mellitus.

结局指标

主要结局

Comparison of change from baseline in Universal Pain Assessment scale at day 30 between GROUP I and GROUP II

时间窗: 30 Days

次要结局

  • To assess the safety of the drug(To review the pharmacological activity)

研究者

发起方
Government siddha medical college and hospital
申办方类型
Other [Govt Siddha Medical college and Hospital]

研究点 (1)

Loading locations...

相似试验